HOUSTON--(BUSINESS WIRE)--Oncolin Therapeutics, Inc., (OTCBB:OCOL) is pleased to announce the addition of Sandra Silberman, M.D., Ph.D. to a growing list of prestigious oncologists and cancer scientists joining its Scientific Advisory Board (SAB). Dr. Silberman is a world renowned oncologist who received her PhD from the John Hopkins University, an M.D. from Cornell University Medical School followed by a residency at the NYU Medical Center. Dr. Silberman did further post graduate training as a research fellow at Harvard Medical School / Dan Farber Cancer Institute and as a clinical fellow at Harvard Medical School / Brigham & Women’s Hospital.
